| Title: |
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update) |
| Authors: |
Aalok Kumar; Katarzyna J. Jerzak; Karen A. Gelmon; Jean-François Boileau; Nathaniel Bouganim; Christine Brezden-Masley; Jeffrey Q. Cao; David W. Cescon; Stephen Chia; Scott Edwards; Anil Abraham Joy; Kara Laing; Nathalie LeVasseur; Sandeep Sehdev; Christine Simmons; Marc Webster; Mita Manna; on behalf of Patient Advocacy, Breast Cancer Canada on behalf of Patient Advocacy, Breast Cancer Canada |
| Source: |
Current Oncology ; Volume 33 ; Issue 4 ; Pages: 200 |
| Publisher Information: |
Multidisciplinary Digital Publishing Institute |
| Publication Year: |
2026 |
| Collection: |
MDPI Open Access Publishing |
| Subject Terms: |
antibody–drug conjugate; breast cancer; HER2-positive; HER2+; HER2-directed therapy; REAL Alliance |
| Description: |
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype associated with a poor prognosis when not optimally treated. Over the past year, major advances—including results from DESTINY-Breast05, DESTINY-Breast09, DESTINY-Breast11, PATINA, and long-term APHINITY follow-up—have changed the treatment landscape regarding the place in therapy of antibody–drug conjugates and the optimal sequencing of systemic therapies. These developments prompted the need for updated evidence-informed consensus recommendations to support consistent, high-quality care across Canada. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), comprising clinical-academic oncologists from across Canada and Breast Cancer Canada, updated its 2024 HER2+ recommendations through a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% agreement. This 2025 update incorporates new data in early-stage, metastatic, and central nervous system-involved disease, including revisions to neoadjuvant and adjuvant treatment pathways and expanded guidance on the clinical use of antibody–drug conjugates. |
| Document Type: |
text |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
Breast Cancer; https://dx.doi.org/10.3390/curroncol33040200 |
| DOI: |
10.3390/curroncol33040200 |
| Availability: |
https://doi.org/10.3390/curroncol33040200 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.5CC50FFC |
| Database: |
BASE |